CNBX · CNBX Pharmaceuticals Inc. · Investor Relations

Substantial doubt about the company's ability to continue as a going concern.

“While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.”